Compare NEULAND LABS with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS IPCA LABS NEULAND LABS/
IPCA LABS
 
P/E (TTM) x 47.8 22.2 215.9% View Chart
P/BV x 3.6 7.9 45.7% View Chart
Dividend Yield % 0.1 0.2 65.3%  

Financials

 NEULAND LABS   IPCA LABS
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
IPCA LABS
Mar-19
NEULAND LABS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs7541,042 72.3%   
Low Rs247590 41.9%   
Sales per share (Unadj.) Rs594.5298.6 199.1%  
Earnings per share (Unadj.) Rs12.635.0 36.1%  
Cash flow per share (Unadj.) Rs37.049.4 74.9%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.40.4 108.7%  
Book value per share (Unadj.) Rs553.4247.1 223.9%  
Shares outstanding (eoy) m12.83126.35 10.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x0.82.7 30.8%   
Avg P/E ratio x39.623.3 169.9%  
P/CF ratio (eoy) x13.516.5 81.9%  
Price / Book Value ratio x0.93.3 27.4%  
Dividend payout %15.88.6 184.7%   
Avg Mkt Cap Rs m6,421103,108 6.2%   
No. of employees `0001.313.4 9.5%   
Total wages/salary Rs m1,2367,874 15.7%   
Avg. sales/employee Rs Th5,949.42,807.0 211.9%   
Avg. wages/employee Rs Th963.8585.8 164.5%   
Avg. net profit/employee Rs Th126.4329.0 38.4%   
INCOME DATA
Net Sales Rs m7,62737,732 20.2%  
Other income Rs m39577 6.7%   
Total revenues Rs m7,66638,309 20.0%   
Gross profit Rs m1,0196,901 14.8%  
Depreciation Rs m3131,824 17.1%   
Interest Rs m216189 114.3%   
Profit before tax Rs m5295,465 9.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3671,042 35.2%   
Profit after tax Rs m1624,422 3.7%  
Gross profit margin %13.418.3 73.0%  
Effective tax rate %69.419.1 363.7%   
Net profit margin %2.111.7 18.1%  
BALANCE SHEET DATA
Current assets Rs m5,15223,778 21.7%   
Current liabilities Rs m3,57610,975 32.6%   
Net working cap to sales %20.733.9 60.9%  
Current ratio x1.42.2 66.5%  
Inventory Days Days105104 101.3%  
Debtors Days Days9166 137.8%  
Net fixed assets Rs m3,96920,368 19.5%   
Share capital Rs m129253 51.0%   
"Free" reserves Rs m6,97130,971 22.5%   
Net worth Rs m7,10031,224 22.7%   
Long term debt Rs m7741,409 54.9%   
Total assets Rs m12,31045,507 27.1%  
Interest coverage x3.530.0 11.5%   
Debt to equity ratio x0.10 241.6%  
Sales to assets ratio x0.60.8 74.7%   
Return on assets %3.110.1 30.3%  
Return on equity %2.314.2 16.1%  
Return on capital %9.517.3 54.6%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m5,18717,308 30.0%   
Fx outflow Rs m1,5936,266 25.4%   
Net fx Rs m3,59411,042 32.5%   
CASH FLOW
From Operations Rs m5734,923 11.6%  
From Investments Rs m-487-1,563 31.1%  
From Financial Activity Rs m-55-1,832 3.0%  
Net Cashflow Rs m331,528 2.1%  

Share Holding

Indian Promoters % 36.3 45.9 79.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 11.4 559.0%  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 17.4 366.3%  
Shareholders   12,705 36,892 34.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   JUBILANT PHARMOVA   DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare NEULAND LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Surged 1,147 Points Today(Closing)

Indian share markets continued their momentum and ended their day on a strong note today.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Mar 3, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 8-QTR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS